


Phosphate Replacement Guideline



PHOSPHATE

PRESENTATION:	<p>1) Sodium glycerophosphate 21.6%: 20ml ampoules containing 20mmol glycerophosphate (1mmol/ml) and 40mmol sodium.</p> <p>2) Potassium acid phosphate 13.6%: 10ml ampoules containing 10mmol phosphate (1mmol/ml) and 10mmol potassium.</p> <p>3) Phosphate 500ml polyfusor containing 50mmol phosphate, 9.5mmol potassium and 81mmol sodium.</p>
INDICATION:	<p>Hypophosphataemia.</p> <p>See previous page.</p>
DOSE AND ADMINISTRATION:	<p>The dose and choice of intravenous preparation will depend on the serum electrolytes and on renal function. Caution in renal insufficiency.</p> <p>Sodium Glycerophosphate (21.6%):</p> <p>Central iv administration: 20mmol (20mls) in 50mls glucose 5% over 5 hours (This contains 40mmols sodium).</p> <p>40mmol (40mls) in 100mls glucose 5% over 5 hours (This contains 80mmol sodium).</p> <p>Peripheral iv administration: 20mmols (20mls) in 250mls glucose 5% over 5 hours (This contains 40mmols sodium).</p> <p>40mmols (40mls) in 500mls glucose 5% over 5 hours (This contains 80mmol sodium).</p> <p>Please remove a volume of glucose 5% from the 50ml and 100ml infusion bags, equivalent to the volume of phosphate preparation to be added to the bag.</p>

	<p>If hypernatraemia is a concern use: Potassium Acid Phosphate (13.6%):</p> <p>Central administration: 20mmols (20mls) in 50mls glucose 5% over 5 hours (This contains 20mmols potassium).</p> <p>40mmols (40mls) in 100mls glucose 5 over 5 hours (This contains 40mmols potassium).</p> <p>Please remove a volume of glucose 5% from the 50ml and 100ml infusion bags, equivalent to the volume of phosphate preparation to be added to the bag.</p> <p>Phosphate polyfusor:</p> <p>Central or peripheral IV administration: 500ml polyfusor administered over 12 hours (Can be given centrally over 6 hours if required).</p>
STABILITY:	<p>Physically and chemically stable for 24 hours at room temperature.</p> <p>Sodium glycerophosphate is also stable in sodium chloride 0.9%.</p>

References:

1. Sodium glycerophosphate. Medusa. NHS Injectable Medicines Guide. Date published 5/07/22.
<https://www.medusaimg.nhs.uk/IVGuideDisplay.asp>
2. Phosphate polyfusor. Medusa. NHS Injectable Medicines Guide. Date published 04/10/23
<https://www.medusaimg.nhs.uk/IVGuideDisplay.asp>
3. Sterile Potassium acid phosphate solution (13.6%). Summary of Product Characteristics.
<https://www.medicines.org.uk/emc/product/3572/smpc#gref> Last updated on emc, 02/01/2015.
4. Geerse D, Bindels A J et al. Treatment of hypophosphatemia in the intensive care unit: a review. *Critical Care* 2010, 14:R14

Title: Phosphate	
ID: Version 4	Authors: C Hannah, A Neally, F Clarke, H Veitch, Dr S Keating, Dr A Hurry.
Status Draft/Final: Final	Approved by: Lothian Critical Care QIT Editorial Group.
	Written: November 2023
Updated on:	Next review : November 2025